- Conditions
- Acute Myelogenous Leukemia, Myelodysplastic Syndrome
- Interventions
- Preparative Regimen, Intravenous Recombinant Human IL-15 (rhIL-15)
- Drug · Biological
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2809–2832
of 16,863
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Fibrosis, Focal Glomerulosclerosis, Kidney Failure, Nephrotic Syndrome, Proteinuria
- Interventions
- Pirfenidone
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2008
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Advanced Cancer, Advanced Solid Tumor, Melanoma, Metastasis, Pleural Mesothelioma, Renal Cell Carcinoma, MSI-High, Mismatch Repair Deficiency, Colorectal Cancer, Hepatocellular Carcinoma, Hepatocellular Cancer, Renal Cell Cancer, Kidney Cancer, Skin Cancer, Non Small Cell Lung Cancer, NSCLC, Anaplastic Lymphoma Kinase Genomic Tumor Aberrations, ALK Genomic Tumor Aberrations
- Interventions
- Alintegimod, Ipilimumab, Nivolumab
- Drug
- Lead sponsor
- 7 Hills Pharma, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Lake Mary, Florida • Lebanon, New Hampshire + 2 more
- Conditions
- Depression, HIV Infections, HIV-Associated Cognitive Motor Complex
- Interventions
- 18F-FDOPA, 11C-DASB
- Drug
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Sepsis
- Interventions
- ClearSight™ / EV1000NI Clinical Platform
- Device
- Lead sponsor
- Edwards Lifesciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 182 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 5
- States / cities
- Detroit, Michigan • Royal Oak, Michigan • Troy, Michigan
- Conditions
- OSA
- Interventions
- Aroxybutynin and Atomoxetine
- Drug
- Lead sponsor
- Apnimed
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,280 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 93
- States / cities
- Birmingham, Alabama • Tuscaloosa, Alabama • Chandler, Arizona + 80 more
- Conditions
- HIV/AIDS
- Interventions
- Behavioral self-regulation Phone counseling to improve HIV care, Behavioral self-regulation Office counseling to improve HIV care
- Behavioral
- Lead sponsor
- University of Connecticut
- Other
- Eligibility
- Not listed
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- HIV Infections
- Interventions
- Nevirapine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 1 Day and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2005
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Fibromyalgia, Myofascial Pain Syndromes, Muscular Diseases, Musculoskeletal Diseases, Nervous System Diseases, Neuromuscular Diseases, Rheumatic Diseases
- Interventions
- TNX-102 SL Tablet, 2.8mg, Placebo SL Tablet
- Drug
- Lead sponsor
- Tonix Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 519 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Sacramento, California + 31 more
- Conditions
- Muscle Oxygenation, Skin Pigmentation
- Interventions
- Measure of muscle oxygenation, Skin pigmentation determination
- Device
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Complex Regional Pain Syndrome
- Interventions
- Botox + Lidocaine, Lidocaine alone
- Drug
- Lead sponsor
- VA Connecticut Healthcare System
- Federal
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- West Haven, Connecticut
- Conditions
- Carcinoid Syndrome, Carcinoid Tumor, Digestive System Neuroendocrine Tumor G1, Metastatic Carcinoid Tumor
- Interventions
- Dual-Energy Computed Tomography
- Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Congenital Heart Block, Neonatal Lupus, Autoantibody-Associated Heart Block
- Interventions
- Hydroxychloroquine
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2020
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Richter Syndrome
- Interventions
- Biopsy, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Fludarabine, Ibrutinib, Lisocabtagene Maraleucel, Nivolumab, Pheresis, Positron Emission Tomography
- Procedure · Drug · Biological
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 2
- States / cities
- Duarte, California • New York, New York
- Conditions
- Common Variable Immunodeficiency (CVID), APDS / PASLI
- Interventions
- CDZ173, Placebo
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- HIV Infections
- Interventions
- Erythromycin, Nevirapine, Clarithromycin
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- HIV Infections
- Interventions
- Not listed
- Lead sponsor
- Baystate Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,087 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Springfield, Massachusetts
- Conditions
- Fever, Cancer, Remote Patient Monitoring
- Interventions
- Remote Patient Monitoring
- Device
- Lead sponsor
- AION Biosystems
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Schenectady, New York
- Conditions
- HIV Infections
- Interventions
- TBC-3B Vaccine, Smallpox Vaccine
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Ends 1996
- U.S. locations
- 5
- States / cities
- St Louis, Missouri • Rochester, New York • Pittsburgh, Pennsylvania + 2 more
- Conditions
- Stimulant Use (Diagnosis), Hiv
- Interventions
- Contingency management
- Behavioral
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Sleep Apnea, Obstructive, Obesity, Overweight
- Interventions
- Eloralintide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 23
- States / cities
- Cullman, Alabama • Long Beach, California • Los Alamitos, California + 19 more
- Conditions
- Sleep Apnea, Obstructive
- Interventions
- Modafinil
- Drug
- Lead sponsor
- Cephalon
- Industry
- Eligibility
- 6 Years to 16 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2005
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Fort Smith, Arkansas + 51 more
- Conditions
- Menopause
- Interventions
- BASIS™ (Crystalline Nicotinamide Riboside 250mg and Pterostilbene 50mg)
- Drug
- Lead sponsor
- University of South Alabama
- Other
- Eligibility
- 35 Years and older · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Mobile, Alabama
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), B-cell Chronic Lymphocytic Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Childhood Renal Cell Carcinoma, Chronic Phase Chronic Myelogenous Leukemia, Clear Cell Renal Cell Carcinoma, de Novo Myelodysplastic Syndromes, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Splenic Marginal Zone Lymphoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, T-cell Large Granular Lymphocyte Leukemia, Type 1 Papillary Renal Cell Carcinoma, Type 2 Papillary Renal Cell Carcinoma, Waldenström Macroglobulinemia
- Interventions
- fludarabine phosphate, total-body irradiation, nonmyeloablative allogeneic hematopoietic stem cell transplantation, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, therapeutic allogeneic lymphocytes, cyclosporine, mycophenolate mofetil, pharmacological study, laboratory biomarker analysis
- Drug · Radiation · Procedure + 2 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 6
- States / cities
- Duarte, California • Stanford, California • Denver, Colorado + 3 more